Study Status
Open to Accrual
DAIDS Number
39208
IND Number
Non-IND study
Clinical Trials Link
Primary Protocol Team Members
Summary
IMPAACT 2050 is a Phase IV study designed to characterize the pharmacokinetics of long-acting injectable cabotegravir (CAB) and rilpivirine (RPV) used in a clinical care setting to treat women living with HIV-1 during pregnancy and postpartum. Women will be followed during pregnancy and then together with their infants through six weeks postpartum.
Site selection was completed in August 2025 and was opened to US-based IMPAACT sites only. Only US sites were invited to participate due to the current market availability of long-acting CAB and RPV.
To contact the clinical research managers for this study, please email impaact.crm2050@frontierscience.org.